TRDA

Entrada Therapeutics, Inc. (TRDA) | Rumor.io

Entrada Therapeutics

TRDA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,935

Bullish sentiment (50-day avg)20%

Price to earnings ratio10.1

Market capitalization242.2M

Earnings per share-3.96

Dividend yield (TTM)—

Revenue (annual)25.4M

Net income (annual)-143.8M

Social

What share of all stock conversation is about TRDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 7

Entrada Therapeutics' Duchenne muscular dystrophy data fell short of expectations, causing the stock to crash, with investors evaluating the platform's validation.
The company's stock plunged after investors concluded that the results were weaker and less differentiated than hoped, with the eev platform appearing less effective than expected.
Entrada Therapeutics announced positive topline results from Cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44, but the results were disappointing, with the stock experiencing a significant decline.

Generated by AI

Sentiment

Of the messages about TRDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -50	28.44% -57.67
Bearish	—	—	100% +50	71.56% +57.67

May 7

The stock price of Entrada Therapeutics, Inc. ($TRDA) has crashed after its Duchenne muscular dystrophy data fell short of expectations, disappointing investors and raising doubts about the company's platform.
Entrada's DMD drug showed lower-than-expected plasma exposure, leading to lackluster data, and the company's stock has lost a significant portion of its value.
Entrada's next-gen Duchenne therapy failed to deliver, and the company's stock is now trading at a significant discount, with some investors questioning the company's board and leadership after the disappointing results.

Generated by AI

Topics

Of the messages about TRDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	86.09%
Controversies	—	—	100%	5.96%
Analysts	—	—	0%	5.3%
Earnings	—	—	0%	1.32%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1.32%

Jun 24

Entrada Therapeutics has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular Dystrophy (DMD).
The company has reported significant plasma concentration, muscle concentration, and exon skipping in the trial, with no serious adverse events or clinically significant changes observed.
Entrada Therapeutics plans to submit regulatory applications in the fourth quarter of 2024 to initiate separate global Phase 2 clinical trials for ENTR-601-44 and ENTR-601-45 in patients with Duchenne Muscular Dystrophy.

Generated by AI

Community

Of the messages about TRDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	26.69%
Newcomers	100%	100%	100%	73.31%

Regulars· Dec 8

Entrada Therapeutics, Inc. ($TRDA) has partnered with Vertex to develop a treatment for Myotonic Dystrophy Type 1 (DM1) through a four-year collaboration.
The partnership involves the discovery and development of Endosomal Escape Vehicle (EEV) therapeutics, with Vertex and Entrada working together to advance this promising treatment.
Entrada's stock price has surged 18.45% to $20.99, with the company's $250 million deal with Vertex driving the significant increase.

Newcomers· Nov 22

$TRDA is being discussed for its significant price drop of 29% after the FDA kept a clinical hold.
The company, Entrada Therapeutics, is focused on the development of ENTR-601-44 for Duchenne Muscular Dystrophy treatment.
Entrada Therapeutics' updates on ENTR-601-44 are being shared and analyzed by newcomers, highlighting the potential of this asset.

Generated by AI

News

Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead

20d agoInvesting.com

Also Discussed

Investors talking about TRDA also mention

#	Name	Attention
1	WEBs Technology XLK Defined Volatility ETFDVXK	0%0
2	Global X SuperDividend REIT ETFSRET	0%new
3	Meridian Corp.MRBK	0%0
4	Wave Life Sciences Ltd.WVE	0%+0
5	Prelude Therapeutics IncorporatedPRLD	0%0
6	Addex Therapeutics LtdADXN	0%0
7	Replimune Group, Inc.REPL	0%0
8	Foghorn Therapeutics Inc.FHTX	0%new
9	Intapp Inc.INTA	0%0
10	4D Molecular Therapeutics, Inc.FDMT	0%new

Entrada Therapeutics, Inc.

Healthcare
Biotechnology

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics that are designed to reach targets inside cells that have traditionally been difficult to address. Its proprietary Endosomal Escape Vehicle platform supports the delivery of genetic medicine candidates and other therapeutic modalities across multiple tissues, with a current emphasis on neuromuscular and inherited retinal diseases. The company’s pipeline includes programs in development for rare and severe conditions, reflecting its role in advancing novel drug-delivery approaches in biotechnology. Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, and operates as a development-stage company centered on research, clinical development, and platform-driven innovation in precision medicine.

Website

Location

One Design Center Place

Boston, MA, 02210

United States

Social

What share of all stock conversation is about TRDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 7

Entrada Therapeutics' Duchenne muscular dystrophy data fell short of expectations, causing the stock to crash, with investors evaluating the platform's validation.
The company's stock plunged after investors concluded that the results were weaker and less differentiated than hoped, with the eev platform appearing less effective than expected.
Entrada Therapeutics announced positive topline results from Cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44, but the results were disappointing, with the stock experiencing a significant decline.

Generated by AI

Sentiment

Of the messages about TRDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -50	28.44% -57.67
Bearish	—	—	100% +50	71.56% +57.67

May 7

The stock price of Entrada Therapeutics, Inc. ($TRDA) has crashed after its Duchenne muscular dystrophy data fell short of expectations, disappointing investors and raising doubts about the company's platform.
Entrada's DMD drug showed lower-than-expected plasma exposure, leading to lackluster data, and the company's stock has lost a significant portion of its value.
Entrada's next-gen Duchenne therapy failed to deliver, and the company's stock is now trading at a significant discount, with some investors questioning the company's board and leadership after the disappointing results.

Generated by AI

Topics

Of the messages about TRDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	86.09%
Controversies	—	—	100%	5.96%
Analysts	—	—	0%	5.3%
Earnings	—	—	0%	1.32%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1.32%

Jun 24

Entrada Therapeutics has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular Dystrophy (DMD).
The company has reported significant plasma concentration, muscle concentration, and exon skipping in the trial, with no serious adverse events or clinically significant changes observed.
Entrada Therapeutics plans to submit regulatory applications in the fourth quarter of 2024 to initiate separate global Phase 2 clinical trials for ENTR-601-44 and ENTR-601-45 in patients with Duchenne Muscular Dystrophy.

Generated by AI

Community

Of the messages about TRDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	26.69%
Newcomers	100%	100%	100%	73.31%

Regulars· Dec 8

Entrada Therapeutics, Inc. ($TRDA) has partnered with Vertex to develop a treatment for Myotonic Dystrophy Type 1 (DM1) through a four-year collaboration.
The partnership involves the discovery and development of Endosomal Escape Vehicle (EEV) therapeutics, with Vertex and Entrada working together to advance this promising treatment.
Entrada's stock price has surged 18.45% to $20.99, with the company's $250 million deal with Vertex driving the significant increase.

Newcomers· Nov 22

$TRDA is being discussed for its significant price drop of 29% after the FDA kept a clinical hold.
The company, Entrada Therapeutics, is focused on the development of ENTR-601-44 for Duchenne Muscular Dystrophy treatment.
Entrada Therapeutics' updates on ENTR-601-44 are being shared and analyzed by newcomers, highlighting the potential of this asset.

Generated by AI

Entrada Therapeutics

Social

May 7

May 7

Jun 24

Regulars· Dec 8

Newcomers· Nov 22

Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead

Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock

Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares

Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares

Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics

Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock

Also Discussed

Entrada Therapeutics, Inc.

Company Information

Location

Social

May 7

May 7

Jun 24

Regulars· Dec 8

Newcomers· Nov 22

Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead

Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock

Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares

Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares

Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics

Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock

Also Discussed